{"id":20286,"date":"2024-09-04T16:00:00","date_gmt":"2024-09-04T10:30:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=20286"},"modified":"2025-02-05T17:06:14","modified_gmt":"2025-02-05T11:36:14","slug":"nonalcoholic-steatohepatitis-therapeutics-pipeline-analysis","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/nonalcoholic-steatohepatitis-therapeutics-pipeline-analysis","title":{"rendered":"Nonalcoholic Steatohepatitis Treatment Market: Which Pipeline Therapy Will Steal the Spotlight?"},"content":{"rendered":"\n

Nonalcoholic steatohepatitis is one of the most common causes of liver disease in the United States. As per the National Institute of Diabetes and Digestive and Kidney Diseases, only a small number of NAFLD patients<\/a> possess NASH. In 2023, the United States reported the highest number of diagnosed prevalent cases of NASH<\/a>, totaling 9.7 million<\/strong> cases. The EU4 and the UK followed with around 3.8 million<\/strong> cases, while Japan had about 2.6 million<\/strong> cases. Gender-based analysis revealed that males had a higher prevalence of NASH, accounting for 56%<\/strong> of the total cases in 7MM. Japan represented about 16%<\/strong> of the total NASH cases in the 7MM for 2023, with the prevalence expected to rise throughout the study period from 2020 to 2034.<\/p>\n\n\n\n

Severity-specific prevalent cases of Nonalcoholic steatohepatitis (NASH) are divided into the following groups: F0 Stage, F1 Stage, F2 stage, F3 stage, and F4 stage. In the United States, a higher number of cases were observed in the F1 stage compared to others, comprising around 38% of the total diagnosed cases in 2023.<\/p>\n\n\n\n

Currently, the pipeline of the NASH treatment market<\/a> consists of a great deal of drugs. FXR Agonists<\/a>, FGF21 Stimulants, FGF19 Analog, Glucagon-like Peptide-1 (GLP-1) Agonist<\/a>, Peroxisome Proliferator-activated Receptor (PPAR) Regulators<\/a>, THR-\u03b2 Agonists, and some others are the most highlighted class of this indication. Ongoing research and current trials have the potential to change the market. <\/p>\n\n\n\n

<\/p>\n\n\n\n

In 2023, prominent liver disease organizations, including the American Association for the Study of Liver Diseases (AASLD)<\/strong> and the European Association for the Study of the Liver (EASL)<\/strong>, officially redefined Nonalcoholic Steatohepatitis (NASH)<\/strong> to Metabolic Dysfunction-Associated Steatohepatitis (MASH)<\/strong>, aligning the name more closely with its metabolic roots. For the most up-to-date insights, explore our comprehensive MASH Market Report<\/strong><\/a>.<\/p>\n\n\n\n

Medications, including the recently FDA-approved REZDIFFRA (resmetirom), should complement diet and exercise. Liver biopsy remains the definitive diagnostic tool to confirm NASH and assess liver damage. Managing associated conditions like obesity, diabetes, and metabolic syndrome is vital for overall treatment efficacy. However, achieving sustained lifestyle changes and ensuring medication adherence pose significant challenges in NASH management.<\/p>\n\n\n\n

More than 130 key players<\/strong>, including pharma giants such as Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A\/S, Eli Lilly and Company, Madrigal Pharmaceuticals, Inc., Terns, Inc., Intercept Pharmaceuticals, Enyo Pharma, 89bio, Inc., Akero Therapeutics, Inc.<\/strong>, and others are working to bring novel therapies that overcome the roadblocks of NASH treatment pipeline. <\/p>\n\n\n\n

\"Emerging<\/figure>\n\n\n\n

Emerging Therapies for Nonalcoholic steatohepatitis <\/strong><\/p>\n\n\n\n

Pegozafermin: 89bio, Inc<\/strong><\/p>\n\n\n\n

Pegozafermin<\/a> or BIO89-100 is a compound that specifically targets and activates a receptor known as fibroblast growth factor 21 (FGF21). FGF21 is a hormone involved in regulating glucose and lipid metabolism, and it has been shown to have potential therapeutic effects in NASH.<\/p>\n\n\n\n